Bosnia and Herzegovina
Tuberculosis profile
Population  2013 3.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.19 (0.17–0.21) 4.9 (4.4–5.4)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 2.7 (1.3–4.6) 69 (33–120)
Incidence  (includes HIV+TB) 1.7 (1.3–2.3) 46 (33–60)
Incidence (HIV+TB only)        
Case detection, all forms (%) 72 (55–99)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–0.57) 1.6 (0.04–8.5)
MDR-TB cases among notified pulmonary
TB cases
0 (0–6) 2 (0–8)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 643   63
Pulmonary, clinically diagnosed 352   36
Extrapulmonary 163   4
       
Total new and relapse 1 261    
Previously treated, excluding relapses 0    
Total cases notified 1 261    
Among 1 261 new and relapse cases:
12 (<1%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 643 (100%) 63 (61%) 706
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment     1
TB/HIV 2013 Number (%)
TB patients with known HIV status 74 (6)
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 84
Previously treated cases, excluding relapse, registered in 2012 77
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 20
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 17.0
Drug susceptibility testing (per 5 million population) 5.2
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 5.3
% Funded domestically 72%
% Funded internationally 28%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-25 Data: www.who.int/tb/data